Compare Cytokinetics Inc (CYTK) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Plby Group Inc — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Cytokinetics Inc is far larger — about 72.9× Plby Group Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Plby Group Inc for 24 Days on average.
| CYTK | PLBY | |
|---|---|---|
Market Cap | $8.62B | $118.21M |
Volume | 2,594,626 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $2.71 |
52-Week Low | $54.76 | $0.99 |
Typical Hold Time | 19 Days | 24 Days |
Enterprise Value | $8.72B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.91, up 2.93% with bearish technical signals despite strong analyst support. The company shows promising drug development with positive Phase 3 results for aficamten in HCM treatment, though fundamentals remain challenged with a P/S ratio of 114 and negative profit margins. Recent executive stock sales and high cash burn from operations highlight ongoing financial pressures despite growing revenue potential from new drug launches.
The outlook balances significant upside potential from analyst price targets averaging $112.60 against substantial execution risks. While clinical successes position CYTK for growth in cardiovascular treatments, persistent losses and high valuation metrics require careful risk assessment. The stock offers speculative growth opportunity but demands close monitoring of commercialization progress and path to profitability.
PLBY trades at $0.9867, down 3.26% today, amid bearish technical signals but with improving fundamentals. Recent earnings show a Q2 2026 beat, and cash flow turned positive in 2025. The company is expanding leadership to drive growth, yet faces high debt and negative equity. Analyst consensus is 75% buy, reflecting optimism on turnaround efforts.
Outlook hinges on execution of growth initiatives and debt management. Opportunities include brand licensing expansion and media strategy, but risks from high leverage and competitive pressures persist. Investors should weigh improving operational trends against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
